Nanki Y - Search Results

1

Evaluation of the role of intraoperative frozen section and magnetic resonance imaging in endometrial cancer.

Ooka R, Nanki Y, Yamagami W, Kawaida M, Nagai S, Hirano T, Sakai K, Makabe T, Chiyoda T, Kobayashi Y, Kataoka F, Aoki D. Ooka R, et al. Among authors: nanki y. Int J Gynaecol Obstet. 2023 Feb;160(2):554-562. doi: 10.1002/ijgo.14389. Epub 2022 Sep 19. Int J Gynaecol Obstet. 2023. PMID: 35929845

2

Elevated preoperative neutrophil : lymphocyte ratio as a preoperative indicator of mature cystic teratoma with malignant transformation.

Nanki Y, Chiyoda T, Kataoka F, Nomura H, Nakadaira N, Iwasa N, Hashimoto S, Arima H, Susumu N, Aoki D. Nanki Y, et al. J Obstet Gynaecol Res. 2017 Apr;43(4):744-748. doi: 10.1111/jog.13271. Epub 2017 Mar 28. J Obstet Gynaecol Res. 2017. PMID: 28370831 Free PMC article.

3

Prospective feasibility study of neoadjuvant dose-dense paclitaxel plus carboplatin with bevacizumab therapy followed by interval debulking surgery for advanced ovarian, fallopian tube, and primary peritoneal cancer patients.

Iwasa-Inoue N, Nomura H, Kataoka F, Chiyoda T, Yoshihama T, Nanki Y, Sakai K, Kobayashi Y, Yamagami W, Morisada T, Hirasawa A, Aoki D. Iwasa-Inoue N, et al. Among authors: nanki y. Int J Clin Oncol. 2022 Feb;27(2):441-447. doi: 10.1007/s10147-021-02050-3. Epub 2021 Oct 14. Int J Clin Oncol. 2022. PMID: 34648082

4

Efficacy and safety of dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube or peritoneal cancer.

Yoshihama T, Nomura H, Iwasa N, Kataoka F, Hashimoto S, Nanki Y, Hirano T, Makabe T, Sakai K, Yamagami W, Hirasawa A, Aoki D. Yoshihama T, et al. Among authors: nanki y. Jpn J Clin Oncol. 2017 Nov 1;47(11):1019-1023. doi: 10.1093/jjco/hyx118. Jpn J Clin Oncol. 2017. PMID: 28973541

5

Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing.

Nanki Y, Chiyoda T, Hirasawa A, Ookubo A, Itoh M, Ueno M, Akahane T, Kameyama K, Yamagami W, Kataoka F, Aoki D. Nanki Y, et al. Sci Rep. 2020 Jul 28;10(1):12581. doi: 10.1038/s41598-020-69488-9. Sci Rep. 2020. PMID: 32724113 Free PMC article.

6

A prospective cohort study on the safety and efficacy of bevacizumab combined with chemotherapy in Japanese patients with relapsed ovarian, fallopian tube or primary peritoneal cancer.

Nanki Y, Nomura H, Iwasa N, Saotome K, Dozen A, Yoshihama T, Hirano T, Hashimoto S, Chiyoda T, Yamagami W, Kataoka F, Aoki D. Nanki Y, et al. Jpn J Clin Oncol. 2021 Jan 1;51(1):54-59. doi: 10.1093/jjco/hyaa140. Jpn J Clin Oncol. 2021. PMID: 32776094

7

Efficacy and safety of olaparib maintenance monotherapy for Japanese patients with platinum-sensitive relapsed ovarian, fallopian tube, and primary peritoneal cancer.

Yoshihama T, Kuroda Y, Chiyoda T, Takahashi M, Yoshimura T, Saotome K, Nanki Y, Sakai K, Kobayashi Y, Yamagami W, Aoki D. Yoshihama T, et al. Among authors: nanki y. Int J Clin Oncol. 2022 Oct;27(10):1644-1650. doi: 10.1007/s10147-022-02212-x. Epub 2022 Jul 15. Int J Clin Oncol. 2022. PMID: 35835930

8

Germline multigene panel testing revealed a BRCA2 pathogenic variant in a patient with suspected Lynch syndrome.

Yoshihama T, Hirasawa A, Sugano K, Yoshida T, Ushiama M, Ueki A, Akahane T, Nanki Y, Sakai K, Makabe T, Yamagami W, Susumu N, Kameyama K, Kosaki K, Aoki D. Yoshihama T, et al. Among authors: nanki y. Int Cancer Conf J. 2020 Oct 9;10(1):6-10. doi: 10.1007/s13691-020-00449-9. eCollection 2021 Jan. Int Cancer Conf J. 2020. PMID: 33489693 Free PMC article.

9

UGT1A1 polymorphism as a prognostic indicator of stage I ovarian clear cell carcinoma patients treated with irinotecan.

Yoshihama T, Hirasawa A, Nomura H, Akahane T, Nanki Y, Yamagami W, Kataoka F, Tominaga E, Susumu N, Mushiroda T, Aoki D. Yoshihama T, et al. Among authors: nanki y. Jpn J Clin Oncol. 2017 Feb 4;47(2):170-174. doi: 10.1093/jjco/hyw163. Jpn J Clin Oncol. 2017. PMID: 28173214

10

Establishment and characterization of a new malignant peritoneal mesothelioma cell line, KOG-1, from the ascitic fluid of a patient with pemetrexed chemotherapy resistance.

Akahane T, Hirasawa A, Imoto I, Okubo A, Itoh M, Nanki Y, Yoshihama T, Tominaga E, Aoki D. Akahane T, et al. Among authors: nanki y. Hum Cell. 2020 Jan;33(1):272-282. doi: 10.1007/s13577-019-00286-w. Epub 2019 Oct 3. Hum Cell. 2020. PMID: 31583526

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11 results

Search Page

Filters